Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

A New Cure for Painkiller Constipation

Shares of Sucampo Pharmaceuticals soared 24% as the company received an expanded indication for Amitiza, which is now the only FDA-approved oral medication for constipation from taking opioid painkillers for non-cancer pain.

In this video, health-care analyst David Williamson explains what this means for Sucampo and why, despite the size of the market, investors may not want to rush in and grab shares after today's big pop.

Author

The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid